This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/mesh/concept/
n20http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00108/identifier/wikipedia/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00108/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00108/identifier/drugbank/
n5http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n9http://linked.opendata.cz/ontology/mesh/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00108/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00108
rdf:type
n3:Drug
n3:description
Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006.
n3:dosage
n14:271B45EC-363D-11E5-9242-09173F13E4C5 n14:271B45ED-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S: Natalizumab for active Crohn's disease. N Engl J Med. 2003 Jan 2;348(1):24-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12510039 # Patent Information "Link":http://www.patentstorm.us/patents/5840299/fulltext.html
n3:group
approved investigational
n3:halfLife
11 ± 4 days
n3:indication
For treatment of multiple sclerosis.
owl:sameAs
n5:DB00108 n15:DB00108
dcterms:title
Natalizumab
adms:identifier
n17:PA164747191 n19:Natalizumab n22:59075-730-15 n23:DB00108
n3:mechanismOfAction
Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
n3:packager
n20:271B45EA-363D-11E5-9242-09173F13E4C5 n20:271B45E8-363D-11E5-9242-09173F13E4C5 n20:271B45E9-363D-11E5-9242-09173F13E4C5
n3:synonym
Anti-alpha4 integrin Anti-VLA4
n3:volumeOfDistribution
* 5.7 ± 1.9 L [Multiple Sclerosis (MS) Patients] * 5.2 ± 2.8 L [Crohn's Disease (CD) Patients]
n11:hasAHFSCode
n21:92-00-00
n9:hasConcept
n10:M0443607
foaf:page
n7:natalizumab.html n18:tysabri.htm
n11:hasATCCode
n12:L04AA23
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
189261-10-7
n3:category
n3:clearance
* 16 +/- 5 mL/hour [patients with MS who did not have PML receiving the repeat IV administration of a 300 mg dose] * 22 +/- 22 mL/hour [Patients with Crohn's Disease receiving the repeat IV administration of a 300 mg dose]
n3:containedIn
n8:271B45EB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n13:271B45EE-363D-11E5-9242-09173F13E4C5